A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
A phase 2 trial of Carmustine in hodgkin lymphoma and non-hodgkin lymphoma, run by VIVUS LLC, now recruiting.
Overview
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma is a phase 2 interventional study registered as NCT06915246 by VIVUS LLC, with 49 participants planned, started 2025-03-12 and due to reach its primary completion in 2027-03-31. Interventions recorded: VI-0609, BiCNU. Conditions listed: Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
Setting
A Randomized Phase 2 Study of Carmustine Formulated With and Without Ethanol as Part of BEAM Chemotherapy Conditioning for Subjects With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation (AHCT)
Phase
Phase 2
Sponsor
VIVUS LLC
Registry
Enrolled
49
Similar pages
not linked directly; found by shared links- TrialT-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
- TrialA Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Ly
- TrialA Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
- TrialA Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treat
- TrialSafety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- TrialA Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphom
- TrialCD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma
- TrialSurovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL